Bioalliance Pharma

Onxeo S.a.

Onxeo

Bioalliance Pharma Sa

Epi Health, LLC

Lnhc, Inc.

Vectans Pharma

Caroline Lemarchand

Dominique Costantini

Pierre Attali

Vanessa Roulet

Claire Scheuir

Lorraine Zakin

Corey Bloom

Ian Yates

Perrine Pivette

The present application concerns new formulations of belinostat suitable for oral administration, their process of preparation, the pharmaceutical compositions comprising said formulations and their uses thereof.

Oral formulations of belinostat

The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.

Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers

The present invention concerns a pharmaceutical composition comprising an alpha-adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.

A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.

Mucosal bioadhesive slow release carrier for delivering active principles

The present invention relates to the treatment or prevention of mucocutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly suitable for the treatment or prevention of orofacial herpes.

Mucoadhesive buccal tablets for the treatment of orofacial herpes

Growing community of inventors

Paris, France

Caroline Lemarchand